Royalty Pharma (RPRX) Earnings Analysis
Royalty Pharma (RPRX) has no confirmed upcoming earnings date. Last quarter (2026-02-11) it beat with EPS 1.46 USD vs 1.29 USD est (+13.2%). It has beaten estimates in 2/3 recent quarters (67%). Trailing P/E 23.83.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does RPRX next report earnings?
No confirmed upcoming earnings date is currently scheduled for RPRX. This page updates as the calendar is published.
RPRX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-11 | 1.46 USD | 1.29 USD | +13.2% | Beat |
| 2025-05-08 | 1.06 USD | 0.953 USD | +11.2% | Beat |
| 2024-08-08 | 0.96 USD | 0.965 USD | -0.5% | Miss |
Beat rate: 2/3 (67%) over reported quarters with consensus data.
RPRX valuation and analyst view
| Trailing P/E | 23.83 |
|---|---|
| Trailing EPS | 1.916 USD |
| Price / book | 3.68 |
| Dividend yield | 1.55% |
| Market cap | 25.02B |
| Analyst consensus | Buy (11 buy / 0 hold / 0 sell) |
| Avg price target | 52.43 USD |
Related research pages
Frequently asked questions
When is Royalty Pharma (RPRX)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for RPRX. This page updates as the calendar is published.
Did RPRX beat earnings last quarter?
In its 2026-02-11 report, RPRX posted EPS of 1.46 USD versus a 1.29 USD estimate — a beat of 13.2%.
What is RPRX's earnings track record?
Over the last 3 reported quarters with consensus data, RPRX beat estimates 2 times (67%).
What is RPRX's current P/E ratio and EPS?
RPRX trades at a trailing P/E of 23.83 on trailing EPS of 1.9162373491214137 USD.
What do analysts rate RPRX?
Analyst consensus is "Buy" across 11 ratings (0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 52.43 USD.